Bulletin for Prescribers | Pharmacogenomics of agomelatine
Agomelatine (Valdoxan) is not recognised on the Sonic PGx report and this bulletin for prescribers, now available for download, discusses reasons for its exclusion.
In short, the Sonic PGx report does not provide guidance for prescribing agomelatine, as there is insufficient evidence to justify modifying the dose on the basis of specific variants in the genes on this panel.
A recent meta-analysis of randomised control trials has documented that using pharmacogenomic testing to inform the prescribing of antidepressants improves the rate of remission at 10–12 weeks.
Hence, clinicians may be interested to know the potential significance of a pharmacogenomic result for prescribing agomelatine.